Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06343038
Title Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study (PROGNOSTICS)
Acronym PROGNOSTICS
Recruitment Recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors University Hospital, Basel, Switzerland
Indications
Therapies
Age Groups: adult | senior
Covered Countries CHE


No variant requirements are available.